This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mengis, C. Articles by Fey, M. F. Search for Related Content PubMed PubMed Citation Articles by Mengis, C. Articles by Fey, M. F. Social Bookmarking                            What's this?

Assessment of Differences in Patient Populations Selected for or Excluded From Participation in Clinical Phase III Acute Myelogenous Leukemia Trials

From the Institute of Medical Oncology, Central Hematology Laboratory, Inselspital and University of Bern; and Swiss Federal Office of Information Technology, Systems and Telecommunication, Bern, Switzerland.

Address reprint requests to Martin F. Fey, MD, Institute of Medical Oncology, Inselspital, CH-3010 Bern, Switzerland; e-mail: martin.fey{at}insel.ch.

Purpose: To compare patients treated in or outside clinical protocols, using de novo acute myeloid leukemia (AML) as a model disorder.

Patients and Methods: We retrospectively compared the characteristics of all patients with de novo AML diagnosed in the referral area of our university hospital between 1985 and 1994.

Results: Of a total of 170 AML patients, 45% were included in a phase III trial for the treatment of AML and 55% were treated outside a protocol. Another 45 patients were registered only at diagnosis but were treated elsewhere. Nonstudy patients differed significantly from patients included in clinical trials with respect to age and performance status at clinical presentation, comorbidity, and type of AML. The great majority of patients excluded from trial participation showed distinct exclusion criteria, such as advanced age and severe comorbidity. Study patients were treated significantly more often with curative intent and achieved better response and survival. Patients treated in an equivalent manner but outside a protocol showed no significant difference in survival compared with patients enrolled onto a trial.

Conclusion: Study patients were not representative for the entire population of patients with AML; many patients were excluded from phase III trial participation for failure to meet stringent entry criteria. Therefore, results of phase III studies may not be extrapolated to all AML patients but should only be applied to patients who do not differ in substantial characteristics from the study population.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Dohner, E. H. Estey, S. Amadori, F. R. Appelbaum, T. Buchner, A. K. Burnett, H. Dombret, P. Fenaux, D. Grimwade, R. A. Larson, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood, January 21, 2010; 115(3): 453 - 474. [Abstract] [Full Text] [PDF]

				J. M. Rowe Closer to the truth in AML Blood, April 30, 2009; 113(18): 4129 - 4130. [Full Text] [PDF]

				G. Juliusson, P. Antunovic, A. Derolf, S. Lehmann, L. Mollgard, D. Stockelberg, U. Tidefelt, A. Wahlin, and M. Hoglund Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Blood, April 30, 2009; 113(18): 4179 - 4187. [Abstract] [Full Text] [PDF]

				H. D. Klepin and L. Balducci Acute Myelogenous Leukemia in Older Adults Oncologist, March 1, 2009; 14(3): 222 - 232. [Abstract] [Full Text] [PDF]

				T. Pabst, M. Eyholzer, S. Haefliger, J. Schardt, and B. U. Mueller Somatic CEBPA Mutations Are a Frequent Second Event in Families With Germline CEBPA Mutations and Familial Acute Myeloid Leukemia J. Clin. Oncol., November 1, 2008; 26(31): 5088 - 5093. [Abstract] [Full Text] [PDF]

				I. Biasoli, P. Franchi-Rezgui, D. Sibon, J. Briere, E. de Kerviler, C. Thieblemont, V. Levy, C. Gisselbrecht, and P. Brice Analysis of factors influencing inclusion of 102 patients with stage III/IV Hodgkin's lymphoma in a randomized trial for first-line chemotherapy Ann. Onc., November 1, 2008; 19(11): 1915 - 1920. [Abstract] [Full Text] [PDF]

				E. Estey Acute Myeloid Leukemia and Myelodysplastic Syndromes in Older Patients J. Clin. Oncol., May 10, 2007; 25(14): 1908 - 1915. [Abstract] [Full Text] [PDF]

				F. Giles, D. Rizzieri, J. Karp, N. Vey, F. Ravandi, S. Faderl, K. Dad Khan, G. Verhoef, P. Wijermans, A. Advani, et al. Cloretazine (VNP40101M), a Novel Sulfonylhydrazine Alkylating Agent, in Patients Age 60 Years or Older With Previously Untreated Acute Myeloid Leukemia J. Clin. Oncol., January 1, 2007; 25(1): 25 - 31. [Abstract] [Full Text] [PDF]

				S. Palmieri, A. M. D'Arco, M. Celentano, G. Mele, C. Califano, F. Pollio, M. R. D'Amico, and F. Ferrara An antecedent diagnosis of refractory anemia with excess blasts has no prognostic relevance in acute myeloid leukemia of older adult patients Ann. Onc., July 1, 2006; 17(7): 1146 - 1151. [Abstract] [Full Text] [PDF]

				F. R. Appelbaum, H. Gundacker, D. R. Head, M. L. Slovak, C. L. Willman, J. E. Godwin, J. E. Anderson, and S. H. Petersdorf Age and acute myeloid leukemia Blood, May 1, 2006; 107(9): 3481 - 3485. [Abstract] [Full Text] [PDF]